Abbott’s Afinion HbA1c Dx assay was launched as the only rapid point-of-care test cleared by the U.S. Food and Drug Administration to aid healthcare professionals in the diagnosis of diabetes and the assessment of patients’ risk of developing the condition.
Amgen Inc. and Allergan plc announced that the U.S. FDA approved Kanjinti (trastuzumab-anns) for all approved cancer indications of the reference product Herceptin.
Camurus announced that the leading drug dependence journal Addiction published full results from a 48-week, open-label, global Phase 3 study of weekly and monthly Buvidal (prolonged-release buprenorphine), the first long-acting injection medicine to be approved for the treatment of opioid dependence in the EU and Australia.
CMI/Compas, media buying and planning for the nation’s top healthcare companies and part of WPP (NYSE:WPP), announced the creation of the EVP, Group Client Director role, which will be responsible for client satisfaction and client business leadership overall.
inVibe Labs, a market research innovator dedicated to changing the way healthcare organizations listen to their customers, helps healthcare companies better understand the thoughts and feelings of patients and physicians by reading between the lines to uncover meaningful language patterns hidden in plain sight.
EVERSANA™ acquires Alamo Pharma Services and BexR Logistix Telesales to add robust field solutions into growing life science commercial services platform CHICAGO, May 28, 2019 /PRNewswire/ — EVERSANA,™ the leading independent provider of commercial services to the life science industry, today announced the acquisition of Alamo Pharma Services®, Inc. and BexR Logistix®, LLC Telesales […]
CMI/Compas announced the promotion of Justin Freid to EVP, Managing Director, Growth & Innovation.
Bayer announced a five-year partnership with the World Federation of Hemophilia Humanitarian Aid Program, which will bring education, training and Bayer’s full portfolio of recombinant Factor VIII treatments to healthcare professionals in more than 60 countries where access to care is limited.
Evoke, part of Huntsworth plc, announced the acquisition of specialty health communications agency KYNE.
UCB announced that the U.S. Food and Drug Administration approved a New Drug Application for the company’s anti-epileptic drug Nayzilam (midazolam) nasal spray CIV.
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!
